Pot Helps Quitters
Smoke up, smoke less
Is the secret to cutting back on smoking found in pot? A study by a team of researchers at the Clinical Psychopharmacology Unit in London's University College, published in the April issue of Addictive Behaviors, finds that inhaling the marijuana-derived substance cannabidiol significantly reduces the number of cigarettes a smoker lights up.
Cannabidiol derives from cannabis plants, but unlike tetrahydrocannabinol (THC), the active ingredient in pot, it does not have psychoactive properties. It does, however, seem to reduce the urge to smoke.
The researchers randomly assigned half of 24 smokers an inhaler dosed with cannabidiol and half with placebo inhalers, and instructed them to take a hit off the inhaler whenever they felt an urge to smoke. A week later, those using placebo inhalers showed no differences in the number of cigarettes they smoked, whereas those huffing on the cannabidiol cut their cigarette consumption by about 40 percent. This is potentially very good medicine: A 2005 study in the Journal of the American Medical Association reported that cutting down from a pack a day to half that reduces the risk of lung cancer by 27 percent.
Editor's Note: As of February 29, 2024, commenting privileges on reason.com posts are limited to Reason Plus subscribers. Past commenters are grandfathered in for a temporary period. Subscribe here to preserve your ability to comment. Your Reason Plus subscription also gives you an ad-free version of reason.com, along with full access to the digital edition and archives of Reason magazine. We request that comments be civil and on-topic. We do not moderate or assume any responsibility for comments, which are owned by the readers who post them. Comments do not represent the views of reason.com or Reason Foundation. We reserve the right to delete any comment and ban commenters for any reason at any time. Comments may only be edited within 5 minutes of posting. Report abuses.
Please
to post comments
inhaler dosed with cannabidiol and half with placebo inhalers, and instructed them to take
study by a team of researchers at the Clinical Psychopharmacology Unit in London's University